|
1
|
Duan S, Wang P, Liu F, Huang H, An W, Pan
S and Wang X: Novel immune-risk score of gastric cancer: A
molecular prediction model combining the value of immune-risk
status and chemosensitivity. Cancer Med. 2019. View Article : Google Scholar
|
|
2
|
Lins RR, Oshima CT, Oliveira LA, Silva MS,
Mader AM and Waisberg J: Expression of E-cadherin and wnt pathway
proteins betacatenin, Apc, Tcf-4 and survivin In gastric
adenocarcinoma: Clinical and pathological implication. Arq Bras Cir
Dig. 29:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suarez-Arriaga MC, Torres J,
Camorlinga-Ponce M, Gómez-Delgado A, Piña-Sánchez P, Valdez-Salazar
HA, Ribas-Aparicio RM, Fuentes-Pananá EM and Ruiz-Tachiquín ME: A
proposed method for the relative quantification of levels of
circulating microRNAs in the plasma of gastric cancer patients.
Oncolo Lett. 13:3109–3117. 2017. View Article : Google Scholar
|
|
4
|
Fang WL, Huang KH, Chen JH, Lo SS, Hsieh
MC, Shen KH, Li AF, Niu DM, Chiou SH and Wu CW: Comparison of the
survival difference between AJCC 6th and 7th editions for gastric
cancer patients. World J Surg. 35:2723–2729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen Q, Chen Z, Chen Z, Chen J, Wang R,
Huang C and Yuan W: EphA2 affects the sensitivity of oxaliplatin by
inducing EMT in oxaliplatin-resistant gastric cancer cells.
Oncotarget. 8:47998–48011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn SH, Kang SH, Lee Y, Min SH, Park YS,
Park DJ and Kim HH: Long-term survival outcomes of laparoscopic
gastrectomy for advanced gastric cancer: Five-year results of a
phase II prospective clinical trial. J Gastric Cancer. 19:102–110.
Mar 12–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gubbay J, Collignon J, Koopman P, Capel B,
Economou A, Münsterberg A, Vivian N, Goodfellow P and Lovell-Badge
R: A gene mapping to the sex-determining region of the mouse Y
chromosome is a member of a novel family of embryonically expressed
genes. Nature. 346:245–250. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao J, Zhang JY, Li YH and Ren F:
Decreased expression of SOX9 indicates a better prognosis and
inhibits the growth of glioma cells by inducing cell cycle arrest.
Int J Clin Exp Pathol. 8:10130–10138. 2015.PubMed/NCBI
|
|
9
|
Leung CO, Mak WN, Kai AK, Chan KS, Lee TK,
Ng IO and Lo RC: Sox9 confers stemness properties in hepatocellular
carcinoma through Frizzled-7 mediated Wnt/beta-catenin signaling.
Oncotarget. 7:29371–29386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lefebvre V, Dumitriu B, Penzo-Mendez A,
Han Y and Pallavi B: Control of cell fate and differentiation by
Sry-related high-mobility-group box (Sox) transcription factors.
Int J Biochem Cell Biol. 39:2195–2214. Jun 6–2007.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song W, Kwon GY, Kim JH, Lim JE, Jeon HG,
Il Seo S, Jeon SS, Choi HY, Jeong BC and Lee HM:
Immunohistochemical staining of ERG and SOX9 as potential
biomarkers of docetaxel response in patients with metastatic
castration-resistant prostate cancer. Oncotarget. 7:83735–83743.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raspaglio G, Petrillo M, Martinelli E, Li
Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei
S, Zannoni GF, et al: Sox9 and Hif-2alpha regulate TUBB3 gene
expression and affect ovarian cancer aggressiveness. Gene.
542:173–181. Mar 21–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fazilaty H, Gardaneh M, Akbari P, Zekri A
and Behnam B: SLUG and SOX9 Cooperatively Regulate Tumor Initiating
Niche Factors in Breast Cancer. Cancer microenvironment. Official
journal of the International Cancer Microenviron. 9:71–74. Sep
28–2016.2015. (Epub ahead of print). View Article : Google Scholar
|
|
14
|
Wang X, Liu Y, Liu X, Yang J, Teng G,
Zhang L and Zhou C: MiR-124 inhibits cell proliferation, migration
and invasion by directly targeting SOX9 in lung adenocarcinoma.
Oncol Rep. 35:3115–3121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Z, Wang H, Xia L, Oyang L, Zhou Y,
Zhang B, Chen X, Luo X, Liao Q and Liang: Overexpression of PAK1
Correlates with Aberrant Expression of EMT Markers and Poor
Prognosis in Non-Small Cell Lung Cancer. J Cancer. 8:1484–1491.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Q, Liu X, Liu Z, Zhou Z, Wang Y, Tu J,
Li L, Bao H, Yang L and Tu K: MicroRNA-1296 inhibits metastasis and
epithelial-mesenchymal transition of hepatocellular carcinoma by
targeting SRPK1-mediated PI3K/AKT pathway. Mol Cancer. 16:1032017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li T, Huang H, Shi G, Zhao L, Li T, Zhang
Z, Liu R, Hu Y, Liu H, Yu J and Li G: TGF-beta1-SOX9 axis-inducible
COL10A1 promotes invasion and metastasis in gastric cancer via
epithelial-to-mesenchymal transition. Cell Death & disease.
9:8492018. View Article : Google Scholar
|
|
21
|
Yan J, Huang W, Huang X, Xiang W, Ye C and
Liu J: A negative feedback loop between long noncoding RNA NBAT1
and Sox9 inhibits the malignant progression of gastric cancer
cells. Biosci Rep. 6:2018.
|
|
22
|
Piccolo S, Dupont S and Cordenonsi M: The
biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng Z, Moroishi T and Guan KL: Mechanisms
of Hippo pathway regulation. Genes Dev. 30:1–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnson R and Halder G: The two faces of
Hippo: targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev. Drug Discov. 13:63–79. 2014. View Article : Google Scholar
|
|
25
|
Moon H, Cho K, Shin S, Kim DY, Han KH and
Ro SW: High Risk of Hepatocellular Carcinoma Development in
Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. Int J
Mol Sci. 20:2019. View Article : Google Scholar
|
|
26
|
Ferrari N, Ranftl R, Chicherova I, Slaven
ND, Moeendarbary E, Farrugia AJ, Lam M, Semiannikova M, Westergaard
MCW, Tchou J, et al: Dickkopf-3 links HSF1 and YAP/TAZ signalling
to control aggressive behaviours in cancer-associated fibroblasts.
Nat Comm. 10:1302019. View Article : Google Scholar
|
|
27
|
Janse van Rensburg HJ, Azad T, Ling M, Hao
Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ and
Yang X: The Hippo Pathway Component TAZ Promotes Immune Evasion in
Human Cancer through PD-L1. Cancer Res. 78:1457–1470. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janse van Rensburg HJ and Yang X: The
hippo pathway and cancer immunity: friend or foe? Oncoscience.
5:49–50. 2018.PubMed/NCBI
|
|
30
|
Maugeri-Sacca M and De Maria R: The hippo
pathway in normal development and cancer. Pharmacol Ther.
186:60–72. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gopalkrishna V, Verma H, Kumbhar NS, Tomar
RS and Patil PR: Detection of Mycoplasma species in cell culture by
PCR and RFLP based method: Effect of BM-cyclin to cure infections.
Indian J Med Microbiol. 25:364–368. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gustafsson RK, Engdahl EE and Fogdell-Hahn
A: Development and validation of a Q-PCR based TCID50 method for
human herpesvirus 6. Virol J. 9:3112012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li F, Shi J, Xu Z, Yao X, Mou T, Yu J, Liu
H and Li G: S100A4-MYH9 Axis promote migration and invasion of
gastric cancer cells by inducing TGF-beta-Mediated
epithelial-mesenchymal Transition. J Cancer. 9:3839–3849. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qiu B, Wei W, Zhu J, Fu G and Lu D: EMT
induced by loss of LKB1 promotes migration and invasion of liver
cancer cells through ZEB1-induced YAP signaling. Oncol Lett.
16:6465–6471. Sep 18–2018.(Epub ahead of print). PubMed/NCBI
|
|
37
|
Kong X, Zhao Y, Li X, Tao Z, Hou M and Ma
H: Overexpression of HIF-2alpha-dependent NEAT1 promotes the
progression of non-small cell lung cancer through
miR-101-3p/SOX9/Wnt/beta-Catenin signal Pathway. Cell Physiol
Biochem. 52:368–381. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gnerlich JL, Ding X, Joyce C, Turner K,
Johnson CD, Chen H, Abood GJ, Pappas SG and Aranha GV: Increased
SOX9 expression in premalignant and malignant pancreatic neoplasms.
Ann Surg Oncol. 26:628–634. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wan YP, XM, He HC, Wan S, Hua W, Zen ZC,
Liu YL, Zhou YL, Mo RJ, Zhuo YJ, et al: Expression and Clinical
Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and
Penile Cancer. Oncol Res Treat. 40:15–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qian Y, Xia S and Feng Z: Sox9 mediated
transcriptional activation of FOXK2 is critical for colorectal
cancer cells proliferation. Biochem Biophys Res Commun.
483:475–481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ren X, Zheng D, Guo F, Liu J, Zhang B, Li
H and Tian W: PPARgamma suppressed Wnt/beta-catenin signaling
pathway and its downstream effector SOX9 expression in gastric
cancer cells. Med Oncol. 32:912015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hidaka E, Maeda C, Nakahara K, Wakamura K,
Ishiyama Y, Shimada S, Seki J, Takano Y, Oae S, Enami Y, et al:
High Serum CA19-9 Concentration predicts poor prognosis in elderly
patients with stage IV Colorectal cancer. Gastrointest Tumors.
5:117–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen YL, Zhang Y, Wang J, Chen N, Fang W,
Zhong J, Liu Y, Qin R, Yu X, Sun Z and Gao F: A 17 gene panel for
non-small cell lung cancer prognosis identified through integrative
epigenomic-transcriptomic analyses of hypoxia-induced
epithelial-mesenchymal transition. Mol Oncol. 11:2019.
|
|
44
|
Padthaisong S, Thanee M, Techasen A,
Namwat N, Yongvani P, Liwatthakun A, Hankla K, Sangkhamanon S and
Loilome W: Nimotuzumab inhibits cholangiocarcinoma cell metastasis
via suppression of the epithelial-mesenchymal transition process.
Anticancer Res. 37:3591–3597. 2017.PubMed/NCBI
|
|
45
|
Imani S, Wei C, Cheng J, Khan MA, Fu S,
Yang L, Tania M, Zhang X, Xiao X, Zhang X and Fu J: MicroRNA-34a
targets epithelial to mesenchymal transition-inducing transcription
factors (EMT-TFs) and inhibits breast cancer cell migration and
invasion. Oncotarget. 8:21362–21379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li Q, Wu J, Wei P, Xu Y, Zhuo C, Wang Y,
Li D and Cai S: Overexpression of forkhead box C2 promotes tumor
metastasis and indicates poor prognosis in colon cancer via
regulating epithelial-mesenchymal transition. Am J Cancer Res.
5:2022–2034. 2015.PubMed/NCBI
|
|
47
|
Zhang J, Tian XJ and Xing J: Signal
Transduction Pathways of EMT induced by TGF-beta, SHH, and WNT and
Their Crosstalks. J CLin Med. 4:520162016.
|
|
48
|
Wan L, Pantel K and Kang Y: Tumor
metastasis: moving new biological insights into the clinic. Nat
Med. 19:1450–1464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Park PG, Jo SJ, Kim MJ, et al: Role of
LOXL2 in the epithelial-mesenchymal transition and colorectal
cancer metastasis. Oncotarget. 25:80325–803352017. 2017.
|
|
50
|
Bruner HC and Derksen PWB: Loss of
E-Cadherin-dependent cell-cell adhesion and the development and
progression of cancer. Cold Spring Harb Perspect Biol. 1:2018.
|
|
51
|
Rajic J, Inic-Kanada A, Stein E, Dinić S,
Schuerer N, Uskoković A, Ghasemian E, Mihailović M, Vidaković M,
Grdović N and Barisani-Asenbauer T: Chlamydia trachomatis Infection
Is associated with E-Cadherin promoter methylation, downregulation
of E-Cadherin expression, and Increased expression of fibronectin
and alpha-SMA-Implications for Epithelial-Mesenchymal Transition.
Front Cell Infect Microbiol. 7:2532017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Buhrmann C, Kraehe P, Lueders C, Shayan P,
Goel A and Shakibaei M: Curcumin suppresses crosstalk between colon
cancer stem cells and stromal fibroblasts in the tumor
microenvironment: Potential role of EMT. PLoS One. 9:e1075142014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Reports.
15:642–656. 2014.PubMed/NCBI
|
|
54
|
Han Y: Analysis of the role of the Hippo
pathway in cancer. J Transl Med. 17:1162019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hou J and Zhou J: WWC3 downregulation
correlates with poor prognosis and inhibition of Hippo signaling in
human gastric cancer. OncoTargets Ther. 10:2931–2942. 2017.
View Article : Google Scholar
|
|
56
|
Sharif GM and Wellstein A: Cell density
regulates cancer metastasis via the hippo pathway. Future Oncol.
11:3253–3260. Nov;12.2015.(Epub ahead of print). View Article : Google Scholar
|
|
57
|
Yuan Y, Li D, Li H, Wang L, Tian G and
Dong Y: YAP overexpression promotes the epithelial-mesenchymal
transition and chemoresistance in pancreatic cancer cells. Mol Med
Rep. 13:237–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hua K, Yang W, Song H, Song J, Wei C, Li D
and Fang L: Up-regulation of miR-506 inhibits cell growth and
disrupt the cell cycle by targeting YAP in breast cancer cells. Int
J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI
|
|
59
|
Ling HH, Kuo CC, Lin BX, Huang YH and Lin
CW: Elevation of YAP promotes the epithelial-mesenchymal transition
and tumor aggressiveness in colorectal cancer. Exp Cell Res.
350:218–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shao DD, Xue W, Kral EB, Bhutkar A,
Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et
al: KRAS and YAP1 converge to regulate EMT and tumor survival.
Cell. 158:171–184. Jun 19–2014.(Epub. ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Diep0enbruck M, Waldmeier L, Ivanek R,
Berninger P, Arnold P, van Nimwegen E and Christofori G: Tead2
expression levels control the subcellular distribution of Yap and
Taz, zyxin expression and epithelial-mesenchymal transition. J Cell
Sci. 127:1523–1536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z
and Chen WX: Expression of Yes-associated protein in gastric
adenocarcinoma and inhibitory effects of its knockdown on gastric
cancer cell proliferation and metastasis. Int j Immunopathol
Pharmacol. 25:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sun D, Li X, He Y, Li W, Wang Y, Wang H,
Jiang S and Xin Y: YAP1 enhances cell proliferation, migration, and
invasion of gastric cancer in vitro and in vivo. Oncotarget.
7:81062–81076. 2016. View Article : Google Scholar : PubMed/NCBI
|
